switching from insulin to glp-1 GLP-1-based therapies for type 2 diabetes: single, dual and triple agonists endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome 3 Takeaways from the Landmark

Common GLOW blends combine GHK-Cu + BPC-157 + TB-500, with BPC-157 reducing injection site pain from GHK-Cu

Although serum alcohol levels were not significantly reduced, acetaldehyde levels were substantially lower in the GSH group compared to the placebo group

Tissue Repair and Injury Healing While BPC-157 is well-known for its ability to maintain healthy GI lining, the peptide is also known to stimulate healing in other tissues, including tendons, ligaments, muscles, and bones

doi: 10.1074/jbc.M114.571588 42 ShokolenkoIVenediktovaNBochkarevaAWilsonGLAlexeyevMF

Gewichtsverlies GLP-1-RAs kunnen leiden tot een aanzienlijk gewichtsverlies